Keyphrases
Portal Hypertension
75%
Acute Variceal Bleeding
65%
Variceal Bleeding
59%
Cirrhosis
53%
Cirrhotic Patients
46%
Decompensated Cirrhosis
45%
Hepatitis C Virus
43%
Hepatic Venous Pressure Gradient
41%
Rebleeding
41%
Liver Stiffness
39%
High Risk
38%
Transjugular Intrahepatic Portosystemic Shunt
36%
Beta-blockers
35%
Nonalcoholic Steatohepatitis
34%
Compensated Advanced Chronic Liver Disease (cACLD)
34%
Hepatic Encephalopathy
32%
Clinically Significant Portal Hypertension
31%
Ascites
25%
Rat Model
24%
Hemodynamic Alteration
22%
Transient Elastography
21%
Portal Vein
21%
Liver Disease
21%
Atrophy
20%
Non-alcoholic Fatty Liver Disease (NAFLD)
20%
Variceal Rebleeding
20%
Improved Outcomes
20%
Alpha-1 Antitrypsin Deficiency
20%
Liver-related Mortality
20%
Varices
20%
Hepatitis C Virus Infection
19%
MELD Score
18%
Propranolol
18%
Placebo
17%
Liver Transplantation
16%
Endoscopy
16%
Pharmacological Therapy
16%
Infection Risk
16%
Atorvastatin
16%
Chronic Hepatitis C
15%
Nonselective β-blockers
15%
Post-transfusion Hepatitis
15%
Anti-hepatitis C Virus
15%
Hemodynamic Response
15%
Statins
14%
Splanchnic Vasodilation
14%
Delta Infection
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Hepatitis C
14%
Portal Pressure
14%
Medicine and Dentistry
Liver Cirrhosis
100%
Portal Hypertension
87%
Bleeding
74%
Nonalcoholic Fatty Liver
40%
Transjugular Intrahepatic Portosystemic Shunt
38%
Venous Pressure
37%
Chronic Liver Disease
37%
Hepatic Encephalopathy
32%
Hemodynamic
31%
Varices
28%
Liver Disease
28%
Endoscopy
27%
Placebo
25%
Infection
24%
Observational Study
22%
Drug Therapy
22%
Platelet
21%
Case-Control Study
21%
Transient Elastography
21%
Chronic Hepatitis C
20%
Portosystemic Anastomosis
20%
Alpha 1-Antitrypsin Deficiency
20%
Ascites
19%
Maturity Onset Diabetes of the Young
16%
Liver Fibrosis
15%
Liver Transplantation
14%
Hepatitis C Virus
14%
Ciclonicate
14%
Ligation
14%
Upper Gastrointestinal Bleeding
14%
Child-Pugh Score
13%
Disease Exacerbation
13%
Isosorbide Mononitrate
13%
Acute on Chronic Liver Failure
13%
Hepatic Portal Vein
13%
Meta-Analysis
13%
Spontaneous Portosystemic Shunt
13%
Fibrosis
12%
Randomized Controlled Trial
12%
Bacterial Infection
11%
Diabetes
10%
Antiviral Therapy
10%
Beta Adrenergic Receptor Blocking Agent
10%
Propranolol
10%
Decompensated Liver Cirrhosis
10%
Creatinine
9%
Hepatocellular Carcinoma
9%
Risk Stratification
9%
Hepatitis B Virus
9%
Model For End Stage Liver Disease Score
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cirrhosis
87%
Portal Hypertension
70%
Bleeding
60%
Nonalcoholic Fatty Liver
38%
Liver Disease
36%
Chronic Liver Disease
31%
Placebo
30%
Hepatitis C Virus
26%
Ascites
25%
Hepatitis C
24%
Infection
23%
Hepatic Encephalopathy
21%
Case-Control Study
21%
Delta Agent Hepatitis
20%
Chronic Hepatitis C
20%
Hepatitis Delta Virus
20%
Randomized Controlled Trial
19%
Decompensated Liver Cirrhosis
18%
Propranolol
17%
Liver Fibrosis
17%
Rat Model
16%
Non Insulin Dependent Diabetes Mellitus
16%
Atorvastatin
16%
Antivirus Agent
15%
Beta Adrenergic Receptor Blocking Agent
15%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Ciclonicate
14%
Hepatitis B Virus
14%
Upper Gastrointestinal Bleeding
14%
Observational Study
13%
Alpha 1 Antitrypsin Deficiency
13%
Posttransfusion Hepatitis
13%
Isosorbide Mononitrate
13%
Disease Exacerbation
13%
Droxidopa
13%
Acute on Chronic Liver Failure
13%
Varicosis
12%
Mortality Rate
12%
Virus Infection
12%
Fibrosis
11%
Pharmacotherapy
11%
Simvastatin
11%
Interferon
10%
Superinfection
10%
End Stage Liver Disease
10%
Disease
10%
Mixed Infection
10%
Liver Cell Carcinoma
8%
Statin (Protein)
8%
Creatinine
8%
